Prerpints.org logo
Preprint
Review

Vitamin D: A Bridge between Kidney and Heart

Altmetrics

Downloads

141

Views

53

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

03 April 2024

Posted:

03 April 2024

You are already at the latest version

Alerts
Abstract
Chronic kidney disease (CKD) and cardiovascular disease (CVD) are highly prevalent conditions, each significantly contributing to the global burden of morbidity and mortality. CVD and CKD share a great number of common risk factor, such as hypertension, diabetes, obesity, and smoking among others. Their relationship extends beyond these factors, encompassing intricate interplay between the two systems. Within this complex network of pathophysiological processes, vitamin D has emerged as a potential linchpin, exerting influence over diverse physiological pathways implicated in both CKD and CVD. In recent years, scientific exploration has unveiled a close connection between these two prevalent conditions and vitamin D, a crucial hormone traditionally recognized for its role in bone health. This article aims to provide an extensive review of vitamin D's multifaceted and expanding actions concerning its involvement in CKD and CVD.
Keywords: 
Subject: Medicine and Pharmacology  -   Endocrinology and Metabolism

1. Introduction

Chronic kidney disease (CKD) is a widespread health condition, commonly occurring and associated with a significant burden and significant morbidity. Globally, it has been documented with 697.5 million cases, representing a prevalence of 9.1%. CKD contributes to 35.8 million Disability-Adjusted Life Years (DALYs) and 1.2 million deaths in 2017[1]. Despite being a preventable and treatable condition, CKD is affecting an increasing proportion of the general population. Its prevalence has increased by 29.3%, and the all-age mortality rate has risen by 41.5% between 1990 and 2017. This trend aligns with recent projections, foreseeing CKD to emerge as the fifth leading global cause of mortality by 2024[2].
On the other hand, cardiovascular disease (CVD), despite a continuous expansion of biomedical knowledge and a constant effort in prevention and treatment, remains the primary cause of mortality and morbidity in western countries [3].
CVD and CKD share many common risk factors, such as diabetes, hypertension, smoke, and obesity[4,5,6], and even some protective factors[7]. However, their relation is not limited to a number of common pre-existing predisposing conditions, but is rooted in a more complex and interlinked mutual cross-talk[8].
Individuals with chronic kidney disease often experience an increased risk of cardiovascular issues, such as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death[9,10]. While the occurrence and prevalence of cardiovascular events are already notably higher in those with early CKD stages (stages 1-3) compared to the general population, patients in advanced CKD stages (stages 4-5) face a significantly elevated risk. In this high-risk population, cardiovascular complications, rather than end-stage kidney disease (CKD stage 5), stand out as the primary cause of mortality[11]. Traditional cardiovascular determinant present in CKD are not able to justify this excess risk in CKD, which appears to be an independent CVD risk factor itself[12]. Some evidences suggest that, among the main alterations caused by CKD, accelerated atherosclerotic degeneration and the development of vascular calcification are linked to worse prognosis[13,14]. This could possibly provide an explanatory mechanism for increased CVD damage in CKD patients[15,16].
In this context, Vitamin D naturally emerges as a key factor in promoting both calcium/phosphorus metabolism imbalance, and thus CKD-related vascular calcification, and atherosclerosis, with a great impact on cardiovascular health[17,18]. In this review, the main roles of Vitamin D in kidney and cardiovascular disease will be described.

2. What is Vitamin D?

Vitamin D is a secosteroid, a steroid hormone obtained through dietary intake and by endogenous synthesis requiring exposure to sunlight. Essential vitamins are defined as substances that a living organism cannot produce adequately on its own and must acquire them exclusively from its diet; for this reason, Vitamin D it is not a true “vitamin”. There are six distinct steroid hormones referred to as vitamin D, each with different levels of activity. These include the endogenous precursor cholecalciferol (D3), derived from cholesterol; its partially active hydroxylated derivative, calcidiol (25(OH)D3), synthesized by the liver; and its active dihydroxy-form, calcitriol (1,25(OH)2D3), hydroxylated in the kidneys[19,20]. Additionally, there is a plant-derived form known as ergocalciferol (D2), characterized by a worse pharmacokinetic profile, less biological activity and lower stability than its animal derived analogues[21,22]. Calcitriol’s most known effect is enhancing the absorption of calcium in the intestines and controlling phosphate levels. Vitamin D nuclear receptors (VDRs) are also present in a plethora of tissues, such as breast, brain, breast, lymphocyte and other immune cells, and prostate[23]; thus, it is unsurprising that vitamin D has various pleiotropic effects that are currently still under investigation, such as immune modulation, the onset of cancer, and insulin regulation[24,25]; many other cardiovascular regulatory functions will be described in greater detail in dedicated sections of this article.
The binding of calcitriol with VDR causes a conformational change in the receptor, leading to its heterodimerization with the retinoic acid X-receptor (RXR) (Figure 1). Additionally, VDR can form heterodimers with other members of the steroid receptor gene family[26]. The transactivation of VDR results in the expression or repression of numerous genes, with estimates suggesting that calcitriol influences over 200 genes directly or indirectly, impacting a diverse array of physiological processes[27]. Notably, VDR-DNA binding aids in targeting genes that may undergo further modification by calcitriol. However, it's important to note that in many instances, changes in gene expression are not directly mediated by VDR but involve various co-regulatory elements[28]. These complexes typically include a VDR regulatory component and exhibit significant enzymatic activity[26].

2.1. Vitamin D Deficiency

Vitamin D normal levels are not unanimously established, although many authors recognize that calcidiol serum levels <30ng/mL can be described as “Vitamin D deficiency”[30,31]; levels below 10-12ng/mL, associated with rickets and ostemalacia, are considered severe deficiency[32,33]. Furthermore, the clinical guidelines established by the Endocrine Society Task Force on Vitamin D have set a deficiency cutoff level for vitamin D at 50 nmol/L[30]. It must be noted that, while calcitriol is acknowledged as the active form of vitamin D, its serum levels are not regularly monitored. This is due to its short half-life, susceptibility to exogenous administration, and, most importantly, absence of a standardized assay. Consequently, calcidiol is the predominant biomarker utilized in both clinical and research settings[34]; however, calcidiol and calcitriol deficiency could impact mineral metabolism in different ways[35].
Recent data suggest that low vitamin D levels are common worldwide, varying across different ages and ethnicities, with a prevalence of 24% in the US and 40% in Europe, and over 20% in India and Pakistan[36,37]. In some groups of individuals it can be even more common, such as in subjects with celiac disease or in obese and sedentary subjects [38,39]; in CKD patients, Vitamin D deficiency prevalence can rise up to 85-99%[40,41].
There are some limitations that must be taken into account when pondering these information, hence the great disagreement in a generally acceptable definition of “normal values” of Vitamin D and its deficiency[42]:
  • No consensus on a standardized laboratory assay[43,44,45];
  • Great variability in Vitamin D levels among different populations and ethnicities, both due to genetic and geographical factors[46,47,48,49];
  • Not clear whether the total or the free (unbound to carrier proteins) Vitamin D should be measured[50,51].

3. Vitamin D in the Context of CKD

Chronic kidney disease is one of the main causes of Vitamin D deficiency, and the progressive decline of renal function is associated with its worsening[52,53].
Vitamin D role in kidney health is complex. Its deficiency is both a consequence of kidney disease and a prognostic factor for progression of kidney damage and is linked to graft survival in kidney transplant recipients. Vitamin D is also an extremely important therapeutic target, as its analogues have a role in the treatment of mineral and bone alterations, proteinuria, and in the reduction of kidney inflammation and fibrosis.
Due to various factors, individuals with CKD frequently encounter deficiencies in both calcidiol and calcitriol (Figure 2). CKD hampers the activity of 1α-hydroxylase CYP27B1, the enzyme responsible for hydroxylation of calcidiol into calcitriol[54,55]. Additionally, this deficiency may arise from impaired skin synthesis or prescribed dietary restrictions, limiting the availability of precursors cholecalciferol and ergocalciferol, and from CKD-related proteinuria and uremia which contribute to the depletion of vitamin D binding proteins and 1,25-dihydroxyvitamin D[54].

3.1. Vitamin D in Mineral and Bone Disease

Vitamin D is a key component of calcium/phosphate homeostasis and bone metabolism: in healthy subjects, parathyroid hormone (PTH), fibroblast growth factor-23 (FGF23) and Vitamin D act as deeply interlinked regulators of this delicate and complex physiological mechanism [57,58]. The disruptions in mineral metabolism caused by CKD, rising PTH, and lower Vitamin D levels are presently recognized as integral components of the chronic kidney disease–mineral and bone disorder (CKD-MBD) definition[59].
Vitamin D exerts its effect on calcium homeostasis forming a complex with VDR and RXR, binding to the vitamin D response element to regulate the transcription of various genes, including epithelial calcium channels and calcium-binding proteins[60,61,62]. Subsequently, calcitriol deficiency will result in reduced calcium absorption from the intestine; to counteract this effect and avoid hypocalcemia, PTH activate osteoclasts thus reabsorbing calcium from the bone. In CKD, various mechanisms contribute to the overproduction of PTH, a condition known as secondary hyperparathyroidism (sHPT), a disease totally different from disorders in the parathyroid glands (primary HPT)[56,57].
The clinical implications of CKD-MBD involve parathyroid gland hyperplasia, bone abnormalities, and vascular calcification; as CKD progresses, the parathyroid glands undergo nodular hyperplasia due to persistent overstimulation by hypocalcemia and hyperphosphoremia [57,61,63,64]. The reduced sensitivity to vitamin D and calcium signals, attributed to the loss of respective receptors, further complicates the situation, leading to parathyroidectomy in the most severe cases[59,61,65].
Bone abnormalities, encompassing different patterns under the term renal osteodystrophy, lead to ostheoporosis and an increasing risk of fracture, worsening together with the decline in renal function[66]
The disturbance in mineral homeostasis within CKD-MBD, through the elevated serum phosphate levels leading to deposit of calcium phosphate salts in the arteries walls, heightens the risk of vascular calcification, thereby increasing susceptibility to cardiovascular diseases[65,67,68]. Managing mineral imbalances like hyperphosphatemia and SHPT is still regarded as one of the prevailing approaches for addressing vascular calcification in CKD. This involves the use of phosphate binders in hyperphosphatemic patients at all stages of CKD, along with implementing dietary phosphate restrictions and utilizing calcimimetics[69]. Vitamin D compounds continue to be one of the primary choice for preventing and treating SHPT in CKD[59].

3.2. Vitamin D as RAAS Inhibitor

The role of Vitamin D in renin-angiontensin-aldosterone system (RAAS) inhibition is nowadays undisputed[70,71]. In experimental models of chronic kidney disease, paricalcitol, a synthetic analogue of vitamin D, diminishes the renal expression of renin, the (pro)renin receptor, angiotensinogen, and the type 1 angiotensin receptor. Furthermore, Vitamin D hinders the activity of tumor necrosis factor α converting enzyme (TACE), which controls the shedding of angiotensin-converting enzyme 2 (ACE2), a crucial enzyme responsible for metabolizing angiotensin II in the proximal tubule (Figure 3)[71,72].
Several pioneering studies have found a negative correlation between the concentration of plasma 1,25(OH)2D3 and blood pressure, as well as plasma renin activity, in both normotensive men and individuals with essential hypertension[73,74,75]. It has been documented that supplementation with vitamin D3 reduces blood pressure in individuals with essential hypertension (19, 20). Treatment with 1,25(OH)2D3 also leads to a reduction in blood pressure, plasma renin activity, and angiotensin II levels in patients with hyperparathyroidism[76,77]. Furthermore, exposure to ultraviolet light, necessary for vitamin D biosynthesis, is inversely related to increases in blood pressure and the prevalence of hypertension in the general population, demonstrating blood pressure-lowering effects[78,79]

3.3. Vitamin D and Proteinuria

Proteinuria is one of the main predictors of chronic kidney disease progression and stands out as a potent and autonomous predictor of adverse outcomes in cardiovascular health. Importantly, these associations are significant regardless of the glomerular filtration rate level. Moreover, these connections hold true across populations with varying degrees of risk for kidney disease progression and cardiovascular disease development. The association between proteinuria and CVD persist even at proteinuria levels below existing thresholds for microalbuminuria [80,81]. Being recognized as the main therapeutic target in management of CKD, it is not surprising that international guidelines recommend every possible effort to reduce it to the lowest achievable level[82].
Effective therapies that can reduce proteinuria include inhibitors of RAAS, such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEi)[83,84]. However, their effect is often suboptimal, and possible persisting residual proteinuria is still an important predictor of renal impairment. Since the acknowledgement of potential serious adverse effects of “dual blockade” of RAAS, combined with the lack of evidence of a reduction in mortality and improvement of kidney function of this therapeutic regimen, there has been a need for drugs capable of limiting residual proteinuria[85,86,87].
Several studies reported Vitamin D role in various groups of proteinuric patients: the exact mechanism are still not fully understood, but appears to be due to a inhibition of RAAS, as described earlier in this paper[88], and to a direct effect on podocytes. As they express both VDR and 1- α-hydroxylase, podocytes can produce calcitriol and respond to autocrine or endocrine calcitriol. In cultured podocytes, calcitriol triggers a dose-dependent activation the transcription of the nephrin gene[89,90]. Nephrin serves both structural and signaling functions, working in conjunction with other slit diaphragm components to create a permeable molecular sieve. This sieve primarily accounts for the retention of proteins[91,92].
Vitamin D analogues, such as paricalcitol, have shown a potential in treating residual proteinuria in various subset of patients, including kidney transplant recipients[93,94,95,96]. Despite an increasing number of randomized controlled trial and observational studies, however, the quality of evidence and the strength of the recommendation are not yet able to suggest a routinary use of paricalcitol for the sole aim of reducing proteinuria, but further research is encouraged.

3.4. Anti-Inflammatory Effects

VDRs play a significant role in overseeing processes like inflammation, epithelial-to-mesenchymal transition, and podocyte integrity[97].
Both vitamin D and VDR influence the apoptosis of cultured mouse podocytes and modulate transforming growth factor β (TGFβ) through the nuclear factor κB (NF-κB) pathway; VDR-mediated sequestration of NF-κB signaling also gives Vitamin D potent antiproliferative, prodifferentiative, and immunomodulating activities, thus dampening kidney inflammation[97,98].
Vitamin D also hinders NFκB transactivation by modulating the advanced glycation end-products and their receptor (AGE-RAGE system), a mechanism underlying the progression of various kidney diseases, including diabetic nephropathy, hypertensive nephropathy, obesity-related glomerulopathy, lupus nephritis, amyloidosis, autosomal dominant polycystic kidney disease, and septic acute kidney injury[99,100,101]. It also promotes the production of IL-10 while reducing the production of TNF-α, IL-12, IL-6, and IFN-c, resulting in an antinflammatory cytokine profile[102]. Other research suggest that dendritic cells are the primary target of the immunosuppressive activity induced by Vitamin D. This is because it hinders the differentiation, maturation, and survival of these cells, ultimately resulting in compromised activation of alloreactive T-cells[103]. Moreover, many of the cells engaged in both innate (monocytes, dendritic cells) and adaptive (T-cells, B-cells) immune responses express both CYP27B1 and VDR. This suggests their ability to both synthesize calcitriol from calcidiol and respond to its effects through autocrine and paracrine pathways.
More recently, several studies have shown a great potential of vitamin D immunomodulatory activities in various non-renal immune diseases, such as vitiligo and multiple sclerosis[104,105,106].
The immunomodulatory effect of Vitamin D, and especially its action on T-cells, with the shift toward a less inflammatory and a more tolerogenic phenotype, could be responsible for its potential counteraction of chronic allograft dysfunction, thus enhancing graft survival[107,108,109,110,111]. Despite these considerations, data on the clinical effectiveness of Vitamin D supplementation for prolonging graft survival are controversial; furthermore, many of the available evidences come from observational studies rather than randomized controlled trials[40,112,113,114,115].
The antinflammatory and antiproliferative role of Vitamin D has also important effects on atherosclerosis, as will be better described further in this paper.

4. Interplay between Vitamin D and Cardiovascular Disease

Cardiovascular disease stands as the predominant cause of global mortality and morbidity. Its multifaceted etiology involves an array of risk factors, categorized into modifiable biochemical or physiological characteristics—such as elevated blood pressure, increased plasma total cholesterol, hyperglycemia, obesity, or thrombogenic factors—and nonmodifiable personal characteristics, including age, sex, or a family history of coronary heart disease (CHD) or other atherosclerotic vascular diseases at an early age[116,117].
Significant strides in scientific research have expanded our understanding of cardiovascular disease, uncovering novel therapeutic targets. Among these emerging targets, vitamin D has garnered attention for its potential role in the pathogenesis of various cardiovascular disease[24]. Figure 3 provides a schematic summary of various roles of Vitamin D in the genesis of CVD.
Preprints 103007 g004
Figure 3. Schematic representation of main Vitamin D roles in CVD. RAAS, renin-angiotensin-aldosterone system; HF, heart failure; PTH, parathyroid hormone.
Figure 3. Schematic representation of main Vitamin D roles in CVD. RAAS, renin-angiotensin-aldosterone system; HF, heart failure; PTH, parathyroid hormone.
Preprints 103007 g004

4.1. Hypertension

Untreated high blood pressure (hypertension) poses a significant risk for cardiovascular diseases like coronary artery disease, myocardial infarction, or stroke[118,119]. Research findings indicate that a lack of vitamin D exacerbates the progression of hypertension (HT); thus, Vitamin D deficiency emerges as an autonomous risk factor for elevated blood pressure and plays a role in fostering cardiovascular mortality[119,120,121]
Several mechanisms can explain Vitamin D role in hypertension.
As previously stated, Vitamin D exerts a regulatory activity in RAAS. These effects unsurprisingly show a consequence in the development of hypertension, as confirmed in many studies both on animal and human [122,123]. Vitamin D can reduce sympathetic activity directly related to high plasma levels of renin, which influences vascular tone through an increase in intraglomerular pressure[124].
Beyond that, Vitamin D is involved in calcium homeostasis by increasing renal reabsorption, increasing calcium release from bone by osteoclasts, and stimulating the production of calcium transporters[125]
In addition, Vitamin D acts at the level of peripheral vascular resistance tone by regulating the influx of calcium and thus acting on increased or decreased peripheral vascular resistance; in fact, VDR is also expressed on vascular smooth muscle cells, and directly influences muscle relaxation[125,126].
Vitamin D also appears to have a direct effect on vascular stiffness. Endothelial cells and vascular smooth muscle cells (VSMCs) express 1α-hydrolase, thus gaining the ability to convert calcidiol to calcitriol[127]. Research indicates that inflammatory molecules like TNF-α and lipopolysaccharide activate this enzyme in Human Umbilical Vein Endothelial Cells (HUVECs)[128]. Furthermore, the addition of calcidiol and calcitriol externally attracts monocytes and increases their binding to HUVECs[128]. Macrophage vitamin D activation is less tightly regulated than in the kidney, and, in atherosclerotic lesions, these macrophages penetrate the arterial wall, allowing the activated vitamin to directly influence VSMC[129]s. This can enhance the response to vasopressors, promote calcification, and induce cell dedifferentiation and oxidative stress[130,131,132,133].
Despite these proven effects, Vitamin D supplementation has shown negligible effects in the treatment of hypertension in some recent clinical trials, although some studies are more encouraging. It is possible that our understanding of Vitamin D effects on blood pressure regulation is still too poor to give us the ability to use it effectively in clinical context[134].

4.2. Vitamin D Deficiency in Atherosclerosis

Atherosclerosis overwhelmingly stands as the predominant underlying factor for coronary artery disease, carotid artery disease, and peripheral arterial disease. This is a pathological condition characterized by changes in the wall of the arteries, which lose their elasticity due to the accumulation of calcium, cholesterol, inflammatory cells, and fibrotic material.
Among the many cardiovascular risk factors, an elevated plasma cholesterol level is probably unique in being sufficient to drive the development of atherosclerosis, even in the absence of other known risk factors[135,136,137].
Other risk factors involved in the atherosclerotic process include hypertension, male sex, diabetes mellitus, elevated homocysteine levels, and obesity. These factors contribute to accelerating the process of atherosclerosis triggered by lipoproteins[138].
Among these “classic”, well-established risk factors, several studies have shown possible involvement of Vitamin D in the pathogenesis of atherosclerosis.
Vitamin exerts a direct effect on the cardiovascular system, since VDRs have been found in endothelial cells, vascular smooth muscle cells, endothelial cells, circulating monocytes, macrophages, dendritic cells, activated T lymphocytes, and platelets[139].
Within endothelial cells, vitamin D governs the synthesis of nitric oxide (NO) by modulating the activity of endothelial NO synthase (eNOS). Under pathogenic conditions, oxidative stress caused by excessive production of reactive oxygen species (ROS) facilitates NO degradation and suppresses NO synthesis resulting in reduced NO bioavailability. Nevertheless, Vitamin D opposes the function of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, the producer of ROS, and enhances antioxidant capability by boosting the activity of antioxidant enzymes like superoxide dismutase[140]. 1,25(OH)2D3 has been shown to inhibit the proliferative effects of epidermal growth factor and endothelin on vascular smooth cells (VSMCs), the latter through decreasing the activity of cyclin-dependent kinase 2, which actually regulates the cell cycle machinery[141]. The effects of 1a,25(OH)2D3 on VSMC migration appear to be divergent. At high doses, calcitriol can induce migration of VSMCs. However, at physiological doses, 25(OH)D and calcitriol inhibit the migration and proliferation of VSMCs by reducing vitamin D-binding protein activity, an effect mediated by attenuation of extracellular signal-regulated kinase 1/2 phosphorylation[142]). The decrease in the formation of atherosclerotic lesions resulted from the inhibition of immune responses, wherein at least two types of cells play a crucial role in the effects of vitamin D3 (specifically, CD4+CD25+ Forkhead box protein [Foxp] 3+ regulatory T cells [Tregs] and dendritic cells [DCs])[143]. Additionally, there exists a potential role for vitamin D in the process of vascular calcification.[144]. 1,25-vitamin D showed a significant association with vascular calcification and, quite unexpectedly, it was a negative correlation, revealing that higher serum levels of 1,25-vitamin D were associated with less vascular calcification. Vitamin D, in addition to being involved in calcium deposition in the axillary skeleton, could in fact also regulate calcium deposition in the vascular wall[144].

4.4. The Role of Vitamin D in Heart Failure

Heart failure (HF) is a pathological state characterized by the heart's inability to meet the metabolic demands of the body. The prevalence of HF varies significantly, ranging from 1% to 12%, as documented in comprehensive reports from the United States and Europe[145]. At the core of HF pathology lies the breakdown of compensatory mechanisms designed to ensure sufficient nutrient delivery to tissues. These mechanisms encompass the neurohormonal system, renin-angiotensin system, aldosterone, parietal remodeling, and chronic inflammation[146].
Patients with HF exhibiting low vitamin D levels tend to experience unfavorable outcomes, aligning with established clinical correlations and biomarkers[147]. In the context of HF affecting myocardial cells, the surplus of ionized calcium (Ca2) detrimentally impacts the contraction and relaxation of the heart[148]. Conversely, vitamin D deficiency may perturb the activities of Ca2 in cardiac cells, contributing to fibrosis, intra-organizational inflammation, and cardiomyocyte hypertrophy[149,150]. Additionally, diminished vitamin D levels can induce inflammation, activate the renin-angiotensin system, and lead to endothelial dysfunction[151].
Several epidemiological and observational studies confirmed a higher risk of cardiovascular events and related mortality in patients with Vitamin D deficiency[152,153]; furthermore, this category of individuals shows significantly higher LV wall thickness, diameter and LV mass, and impaired myocardial performance index in comparison to the rest of the population[154,155].
While observational and epidemiological data, together with pathophysiological studies, suggest that vitamin D supplementation may ameliorate ventricular remodeling in HF patients, the clarity of this relationship remains elusive[156].
Evidences from many interventional studies, such as RECORD, EVITA, ViDA, VINDICATE and the most recent VITAL, have shown little or no benefit from Vitamin D supplementation in reducing adverse cardiovascular events or CVD-related mortality[157,158,159,160,161].

4.4. Atrial Fibrillation

Atrial fibrillation (AF), the most prevalent sustained arrhythmia, is linked to substantial morbidity, diminished functional status, compromised quality of life, and heightened mortality, with an adjusted rate of 4.72% per year. A significant proportion of deaths, approximately 46%, are attributed to cardiological causes, encompassing sudden cardiac death, heart failure, and myocardial infarction. In contrast, a minority are associated with nonhemorrhagic strokes (5.7%) or hemorrhagic events (5.6%)[162].
The established risk factors for AF include advanced age, male sex, hypertension, alcohol consumption, and valvular disease, with emerging factors such as hypertrophic cardiomyopathy, obstructive sleep apnea syndrome (OSAS), coronary artery disease, and chronic kidney disease gaining recognition[163,164]. The role of vitamin D in the pathogenesis of atrial fibrillation remains contentious, with divergent findings in the literature. Some studies indicate a positive correlation between hypovitaminosis D and atrial fibrillation, while others do not establish a clear link[165,166]. A plausible correlation may lie in vitamin D's interference with reactive oxygen species (ROS) production in the atrium, contributing to the arrhythmic substrate of atrial fibrillation. Additionally, vitamin D has been observed to negatively modulate the renin-angiotensin-aldosterone system, thereby mitigating atrial remodeling, a phenomenon commonly observed in atrial fibrillation[167].

5. Conclusions

Over decades, since the discovery of its deficiency disease by Casimir Funk[168], vitamin D has captured the attention of scientist from all around the world. This led to the acknowledgement of its various pleiotropic effects, ranging from anti-infective effects, reduction of metabolic complications, to cancer prevention, and, as extensively described, in kidney and cardiovascular health. However, recent findings from randomized clinical trials and meta-analyses have tempered the enthusiasm surrounding the purported "pleiotropic" effects of vitamin D[169]. This is because there is a lack of clear evidence demonstrating the beneficial effects of vitamin D supplementation across various clinical scenarios[122,170,171,172,173,174,175]. On the other hand, inappropriate vitamin D supplementation can lead to serious, although rare, health issues mainly linked to hypercalcemia[176,177,178].
In conclusion, while the pleiotropic effects of vitamin D on kidney and cardiovascular health have been extensively explored, it is essential to acknowledge that conclusive evidence regarding its clinical efficacy is still lacking. Despite numerous studies, the intricate interplay between vitamin D and these health outcomes requires many more years of intensive research for a comprehensive understanding. The journey towards unraveling the true impact of vitamin D on kidney and cardiovascular health remains a complex and evolving path, emphasizing the need for continued scientific exploration in this field.

Author Contributions

Conceptualization, C.S. and G.B.; writing—original draft preparation, C.S. G.C., V.V., S.H., and A.S.; writing—review and editing, C.S., N.V., M.F., S.M., A.R., and F.G.; visualization, E.S.; supervision, G.B.; project administration, G.B.

Funding

none.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bikbov, B.; Purcell, C.A.; Levey, A.S.; Smith, M.; Abdoli, A.; Abebe, M.; Adebayo, O.M.; Afarideh, M.; Agarwal, S.K.; Agudelo-Botero, M.; et al. Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet 2020, 395, 709–733. [Google Scholar] [CrossRef] [PubMed]
  2. Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M.A.; Smith, A.E.; Tang, K.; Yuan, C.-W.; et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016–40 for 195 Countries and Territories. The Lancet 2018, 392, 2052–2090. [Google Scholar] [CrossRef] [PubMed]
  3. Mensah, G.A.; Wei, G.S.; Sorlie, P.D.; Fine, L.J.; Rosenberg, Y.; Kaufmann, P.G.; Mussolino, M.E.; Hsu, L.L.; Addou, E.; Engelgau, M.M.; et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res 2017, 120, 366–380. [Google Scholar] [CrossRef] [PubMed]
  4. Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Chronic Kidney Disease. The Lancet 2017, 389, 1238–1252. [Google Scholar] [CrossRef] [PubMed]
  5. Francula-Zaninovic, S.; Nola, I.A. Management of Measurable Variable Cardiovascular Disease’ Risk Factors. CCR 2018, 14, 153–163. [Google Scholar] [CrossRef] [PubMed]
  6. Di Pietro, P.; Izzo, C.; Carrizzo, A. Editorial: The Role of Metabolic Syndrome and Disorders in Cardiovascular Disease. Front Endocrinol (Lausanne) 2023, 14, 1327394. [Google Scholar] [CrossRef] [PubMed]
  7. Cirillo, M.; Bilancio, G.; Secondulfo, C.; Iesce, G.; Ferrara, C.; Terradura-Vagnarelli, O.; Laurenzi, M. Relation of Alcohol Intake to Kidney Function and Mortality Observational, Population-Based, Cohort Study. Nutrients 2022, 14, 1297. [Google Scholar] [CrossRef] [PubMed]
  8. Izzo, M.; Carrizzo, A.; Izzo, C.; Cappello, E.; Cecere, D.; Ciccarelli, M.; Iannece, P.; Damato, A.; Vecchione, C.; Pompeo, F. Vitamin D: Not Just Bone Metabolism but a Key Player in Cardiovascular Diseases. Life 2021, 11, 452. [Google Scholar] [CrossRef] [PubMed]
  9. Matsushita, K.; Ballew, S.H.; Wang, A.Y.-M.; Kalyesubula, R.; Schaeffner, E.; Agarwal, R. Epidemiology and Risk of Cardiovascular Disease in Populations with Chronic Kidney Disease. Nat Rev Nephrol 2022, 18, 696–707. [Google Scholar] [CrossRef]
  10. Bilancio, G.; Celano, M.; Cozza, V.; Zingone, F.; Palladino, G.; Cirillo, M. Early Prediction of Cardiovascular Disease in Kidney Transplant Recipients. Transplantation Proceedings 2017, 49, 2092–2098. [Google Scholar] [CrossRef]
  11. Jankowski, J.; Floege, J.; Fliser, D.; Böhm, M.; Marx, N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 2021, 143, 1157–1172. [Google Scholar] [CrossRef] [PubMed]
  12. Sarnak, M.J.; Levey, A.S.; Schoolwerth, A.C.; Coresh, J.; Culleton, B.; Hamm, L.L.; McCullough, P.A.; Kasiske, B.L.; Kelepouris, E.; Klag, M.J.; et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108, 2154–2169. [Google Scholar] [CrossRef] [PubMed]
  13. Bover, J.; Evenepoel, P.; Urena-Torres, P.; Vervloet, M.G.; Brandenburg, V.; Mazzaferro, S.; Covic, A.; Goldsmith, D.; Massy, Z.A.; Cozzolino, M.; et al. Pro: Cardiovascular Calcifications Are Clinically Relevant. Nephrology Dialysis Transplantation 2015, 30, 345–351. [Google Scholar] [CrossRef] [PubMed]
  14. Chen, J.; Budoff, M.J.; Reilly, M.P.; Yang, W.; Rosas, S.E.; Rahman, M.; Zhang, X.; Roy, J.A.; Lustigova, E.; Nessel, L.; et al. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol 2017, 2, 635. [Google Scholar] [CrossRef] [PubMed]
  15. Carrizzo, A.; Izzo, C.; Forte, M.; Sommella, E.; Di Pietro, P.; Venturini, E.; Ciccarelli, M.; Galasso, G.; Rubattu, S.; Campiglia, P.; et al. A Novel Promising Frontier for Human Health: The Beneficial Effects of Nutraceuticals in Cardiovascular Diseases. Int J Mol Sci 2020, 21, 8706. [Google Scholar] [CrossRef] [PubMed]
  16. Izzo, C.; Secondulfo, C.; Bilancio, G.; Visco, V.; Virtuoso, N.; Migliarino, S.; Ciccarelli, M.; Di Pietro, P.; La Mura, L.; Damato, A.; et al. Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview. Life 2024, 14, 418. [Google Scholar] [CrossRef] [PubMed]
  17. Danik, J.S.; Manson, J.E. Vitamin D and Cardiovascular Disease. Curr Treat Options Cardio Med 2012, 14, 414–424. [Google Scholar] [CrossRef] [PubMed]
  18. Lavie, C.J.; Lee, J.H.; Milani, R.V. Vitamin D and Cardiovascular Disease. Journal of the American College of Cardiology 2011, 58, 1547–1556. [Google Scholar] [CrossRef] [PubMed]
  19. Demer, L.L.; Hsu, J.J.; Tintut, Y. Steroid Hormone Vitamin D: Implications for Cardiovascular Disease. Circ Res 2018, 122, 1576–1585. [Google Scholar] [CrossRef]
  20. Romano, M.R.; Biagioni, F.; Carrizzo, A.; Lorusso, M.; Spadaro, A.; Micelli Ferrari, T.; Vecchione, C.; Zurria, M.; Marrazzo, G.; Mascio, G.; et al. Effects of Vitamin B12 on the Corneal Nerve Regeneration in Rats. Exp Eye Res 2014, 120, 109–117. [Google Scholar] [CrossRef]
  21. Vieth, R. Vitamin D Supplementation: Cholecalciferol, Calcifediol, and Calcitriol. Eur J Clin Nutr 2020, 74, 1493–1497. [Google Scholar] [CrossRef] [PubMed]
  22. Vieth, R.; Chan, P.-C.R.; MacFarlane, G.D. Efficacy and Safety of Vitamin D3 Intake Exceeding the Lowest Observed Adverse Effect Level. The American Journal of Clinical Nutrition 2001, 73, 288–294. [Google Scholar] [CrossRef] [PubMed]
  23. Bikle, D.D. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chemistry & Biology 2014, 21, 319–329. [Google Scholar] [CrossRef]
  24. Holick, M.F. Vitamin D Deficiency. N Engl J Med 2007, 357, 266–281. [Google Scholar] [CrossRef]
  25. Holick, M.F. VITAMIN D IN HEALTH AND DISEASE: Vitamin D for Health and in Chronic Kidney Disease. Seminars in Dialysis 2005, 18, 266–275. [Google Scholar] [CrossRef] [PubMed]
  26. Pike, J.W.; Meyer, M.B. The Vitamin D Receptor: New Paradigms for the Regulation of Gene Expression by 1,25-Dihydroxyvitamin D3. Endocrinology and Metabolism Clinics of North America 2010, 39, 255–269. [Google Scholar] [CrossRef] [PubMed]
  27. Stivelman, E.; Retnakaran, R. Role of Vitamin D in the Pathophysiology and Treatment of Type 2 Diabetes. CDR 2012, 8, 42–47. [Google Scholar] [CrossRef]
  28. Ellison, T.I.; Dowd, D.R.; MacDonald, P.N. Calmodulin-Dependent Kinase IV Stimulates Vitamin D Receptor-Mediated Transcription. Molecular Endocrinology 2005, 19, 2309–2319. [Google Scholar] [CrossRef] [PubMed]
  29. Latic, N.; Erben, R.G. Vitamin D and Cardiovascular Disease, with Emphasis on Hypertension, Atherosclerosis, and Heart Failure. IJMS 2020, 21, 6483. [Google Scholar] [CrossRef]
  30. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 2011, 96, 1911–1930. [Google Scholar] [CrossRef]
  31. Dietary Reference Intakes for Calcium and Vitamin D; National Academies Press: Washington, D.C., 2011; p. 13050; ISBN 978-0-309-16394-1.
  32. Munns, C.F.; Shaw, N.; Kiely, M.; Specker, B.L.; Thacher, T.D.; Ozono, K.; Michigami, T.; Tiosano, D.; Mughal, M.Z.; Mäkitie, O.; et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. The Journal of Clinical Endocrinology & Metabolism 2016, 101, 394–415. [Google Scholar] [CrossRef]
  33. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Dietary Reference Values for Vitamin D. EFS2 2016, 14. [CrossRef]
  34. Jacobs, E.T.; Martínez, M.E.; Jurutka, P.W. Vitamin D: Marker or Mechanism of Action? Cancer Epidemiology, Biomarkers & Prevention 2011, 20, 585–590. [Google Scholar] [CrossRef]
  35. Cirillo, M.; Bilancio, G.; Guarino, E.; Cavallo, P.; Lombardi, C.; Costanzo, S.; De Curtis, A.; Di Castelnuovo, A.; Iacoviello, L. Vitamin D Status and Indices of Mineral Homeostasis in the Population: Differences Between 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D. Nutrients 2019, 11, 1777. [Google Scholar] [CrossRef] [PubMed]
  36. Cashman, K.D. Vitamin D Deficiency: Defining, Prevalence, Causes, and Strategies of Addressing. Calcif Tissue Int 2020, 106, 14–29. [Google Scholar] [CrossRef] [PubMed]
  37. Cashman, K.D.; Dowling, K.G.; Škrabáková, Z.; Gonzalez-Gross, M.; Valtueña, J.; De Henauw, S.; Moreno, L.; Damsgaard, C.T.; Michaelsen, K.F.; Mølgaard, C.; et al. Vitamin D Deficiency in Europe: Pandemic? The American Journal of Clinical Nutrition 2016, 103, 1033–1044. [Google Scholar] [CrossRef] [PubMed]
  38. Ciacci, C.; Bilancio, G.; Russo, I.; Iovino, P.; Cavallo, P.; Santonicola, A.; Bucci, C.; Cirillo, M.; Zingone, F. 25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D, and Peripheral Bone Densitometry in Adults with Celiac Disease. Nutrients 2020, 12, 929. [Google Scholar] [CrossRef] [PubMed]
  39. Cirillo, M.; Bilancio, G.; Cavallo, P.; Costanzo, S.; De Curtis, A.; Di Castelnuovo, A.; Iacoviello, L. Correlates of Calcidiol Deficiency in Adults-Cross-Sectional, Observational, Population-Based Study. Nutrients 2022, 14, 459. [Google Scholar] [CrossRef] [PubMed]
  40. Courbebaisse, M.; Alberti, C.; Colas, S.; Prié, D.; Souberbielle, J.-C.; Treluyer, J.-M.; Thervet, E. VITamin D Supplementation in renAL Transplant Recipients (VITALE): A Prospective, Multicentre, Double-Blind, Randomized Trial of Vitamin D Estimating the Benefit and Safety of Vitamin D3 Treatment at a Dose of 100,000 UI Compared with a Dose of 12,000 UI in Renal Transplant Recipients: Study Protocol for a Double-Blind, Randomized, Controlled Trial. Trials 2014, 15, 430. [Google Scholar] [CrossRef]
  41. Zhou, Q.; Li, L.; Chen, Y.; Zhang, J.; Zhong, L.; Peng, Z.; Xing, T. Vitamin D Supplementation Could Reduce the Risk of Acute Cellular Rejection and Infection in Vitamin D Deficient Liver Allograft Recipients. International Immunopharmacology 2019, 75, 105811. [Google Scholar] [CrossRef]
  42. Messa, P.; Regalia, A.; Alfieri, C. Nutritional Vitamin D in Renal Transplant Patients: Speculations and Reality. Nutrients 2017, 9, 550. [Google Scholar] [CrossRef] [PubMed]
  43. Binkley, N.; Krueger, D.; Lensmeyer, G. 25-Hydroxyvitamin D Measurement, 2009: A Review for Clinicians. Journal of Clinical Densitometry 2009, 12, 417–427. [Google Scholar] [CrossRef] [PubMed]
  44. Farrell, C.-J.L.; Martin, S.; McWhinney, B.; Straub, I.; Williams, P.; Herrmann, M. State-of-the-Art Vitamin D Assays: A Comparison of Automated Immunoassays with Liquid Chromatography–Tandem Mass Spectrometry Methods. Clinical Chemistry 2012, 58, 531–542. [Google Scholar] [CrossRef] [PubMed]
  45. Fraser, W.D.; Milan, A.M. Vitamin D Assays: Past and Present Debates, Difficulties, and Developments. Calcif Tissue Int 2013, 92, 118–127. [Google Scholar] [CrossRef] [PubMed]
  46. Freedman, B.I.; Register, T.C. Effect of Race and Genetics on Vitamin D Metabolism, Bone and Vascular Health. Nat Rev Nephrol 2012, 8, 459–466. [Google Scholar] [CrossRef]
  47. Levin, G.P.; Robinson-Cohen, C.; De Boer, I.H.; Houston, D.K.; Lohman, K.; Liu, Y.; Kritchevsky, S.B.; Cauley, J.A.; Tanaka, T.; Ferrucci, L.; et al. Genetic Variants and Associations of 25-Hydroxyvitamin D Concentrations With Major Clinical Outcomes. JAMA 2012, 308, 1898. [Google Scholar] [CrossRef] [PubMed]
  48. Brodie, A.M.; Lucas, R.M.; Harrison, S.L.; Van Der Mei, I.A.F.; Armstrong, B.; Kricker, A.; Mason, R.S.; McMichael, A.J.; Nowak, M.; Whiteman, D.C.; et al. The AusD Study: A Population-Based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range. American Journal of Epidemiology 2013, 177, 894–903. [Google Scholar] [CrossRef] [PubMed]
  49. Powe, C.E.; Evans, M.K.; Wenger, J.; Zonderman, A.B.; Berg, A.H.; Nalls, M.; Tamez, H.; Zhang, D.; Bhan, I.; Karumanchi, S.A.; et al. Vitamin D–Binding Protein and Vitamin D Status of Black Americans and White Americans. N Engl J Med 2013, 369, 1991–2000. [Google Scholar] [CrossRef]
  50. Denburg, M.R.; Hoofnagle, A.N.; Sayed, S.; Gupta, J.; De Boer, I.H.; Appel, L.J.; Durazo-Arvizu, R.; Whitehead, K.; Feldman, H.I.; Leonard, M.B.; et al. Comparison of Two ELISA Methods and Mass Spectrometry for Measurement of Vitamin D-Binding Protein: Implications for the Assessment of Bioavailable Vitamin D Concentrations Across Genotypes. Journal of Bone and Mineral Research 2016, 31, 1128–1136. [Google Scholar] [CrossRef]
  51. Bikle, D.; Bouillon, R.; Thadhani, R.; Schoenmakers, I. Vitamin D Metabolites in Captivity? Should We Measure Free or Total 25(OH)D to Assess Vitamin D Status? The Journal of Steroid Biochemistry and Molecular Biology 2017, 173, 105–116. [Google Scholar] [CrossRef]
  52. Franca Gois, P.H.; Wolley, M.; Ranganathan, D.; Seguro, A.C. Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. Int J Environ Res Public Health 2018, 15, 1773. [Google Scholar] [CrossRef]
  53. Li, M.; Li, Y. Prevalence and Influencing Factors of Vitamin D Deficiency in Chronic Kidney Disease: A Cross-Sectional Study. Int J Clin Pharmacol Ther 2020, 58, 595–600. [Google Scholar] [CrossRef]
  54. Nigwekar, S.U.; Tamez, H.; Thadhani, R.I. Vitamin D and Chronic Kidney Disease–Mineral Bone Disease (CKD–MBD). BoneKEy Reports 2014, 3. [Google Scholar] [CrossRef] [PubMed]
  55. Zhou, S.; Glowacki, J. Chronic Kidney Disease and Vitamin D Metabolism in Human Bone Marrow–Derived MSCs. Annals of the New York Academy of Sciences 2017, 1402, 43–55. [Google Scholar] [CrossRef]
  56. Brandenburg, V.; Ketteler, M. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future. Nutrients 2022, 14, 3009. [Google Scholar] [CrossRef]
  57. Fusaro, M.; Pereira, L.; Bover, J. Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease–Mineral and Bone Disorder in Non-Dialysis Adult Patients. Journal of Clinical Medicine 2023, 12, 6306. [Google Scholar] [CrossRef]
  58. Pascale, A.V.; Finelli, R.; Giannotti, R.; Visco, V.; Fabbricatore, D.; Matula, I.; Mazzeo, P.; Ragosa, N.; Massari, A.; Izzo, R.; et al. Vitamin D, Parathyroid Hormone and Cardiovascular Risk: The Good, the Bad and the Ugly. J Cardiovasc Med (Hagerstown) 2018, 19, 62–66. [Google Scholar] [CrossRef] [PubMed]
  59. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements 2017, 7, 1–59. [CrossRef] [PubMed]
  60. Galuška, D.; Pácal, L.; Kaňková, K. Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease. Kidney Blood Press Res 2021, 46, 152–161. [Google Scholar] [CrossRef]
  61. Cunningham, J.; Locatelli, F.; Rodriguez, M. Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clinical Journal of the American Society of Nephrology 2011, 6, 913–921. [Google Scholar] [CrossRef]
  62. Christensen, M.H.E.; Apalset, E.M.; Nordbø, Y.; Varhaug, J.E.; Mellgren, G.; Lien, E.A. 1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism. PLOS ONE 2013, 8, e56019. [Google Scholar] [CrossRef]
  63. Drueke, T.; Martin, D.; Rodriguez, M. Can Calcimimetics Inhibit Parathyroid Hyperplasia? Evidence from Preclinical Studies. Nephrol Dial Transplant 2007, 22, 1828–1839. [Google Scholar] [CrossRef]
  64. Rodriguez, M.; Nemeth, E.; Martin, D. The Calcium-Sensing Receptor: A Key Factor in the Pathogenesis of Secondary Hyperparathyroidism. American Journal of Physiology-Renal Physiology 2005, 288, F253–F264. [Google Scholar] [CrossRef]
  65. Ketteler, M.; Bover, J.; Mazzaferro, S. Treatment of Secondary Hyperparathyroidism in Non-Dialysis CKD: An Appraisal 2022s. Nephrology Dialysis Transplantation 2023, 38, 1397–1404. [Google Scholar] [CrossRef]
  66. Naylor, K.L.; McArthur, E.; Leslie, W.D.; Fraser, L.-A.; Jamal, S.A.; Cadarette, S.M.; Pouget, J.G.; Lok, C.E.; Hodsman, A.B.; Adachi, J.D.; et al. The Three-Year Incidence of Fracture in Chronic Kidney Disease. Kidney International 2014, 86, 810–818. [Google Scholar] [CrossRef]
  67. Yamada, S.; Giachelli, C.M. Vascular Calcification in CKD-MBD: Roles for Phosphate, FGF23, and Klotho. Bone 2017, 100, 87–93. [Google Scholar] [CrossRef]
  68. Cirillo, C.; Bilancio, G.; Natale, F.; Concilio, C.; Russo, M.G.; Calabrò, P.; Cirillo, M. Cardiovascular Calcification and Subcortical Bone Demineralization in Hypertension. Hypertens Res 2017, 40, 825–830. [Google Scholar] [CrossRef]
  69. Reiss, A.B.; Miyawaki, N.; Moon, J.; Kasselman, L.J.; Voloshyna, I.; D’Avino, R.; De Leon, J. CKD, Arterial Calcification, Atherosclerosis and Bone Health: Inter-Relationships and Controversies. Atherosclerosis 2018, 278, 49–59. [Google Scholar] [CrossRef]
  70. Li, Y.C.; Kong, J.; Wei, M.; Chen, Z.-F.; Liu, S.Q.; Cao, L.-P. 1,25-Dihydroxyvitamin D3 Is a Negative Endocrine Regulator of the Renin-Angiotensin System. J. Clin. Invest. 2002, 110, 229–238. [Google Scholar] [CrossRef]
  71. Freundlich, M.; Quiroz, Y.; Zhang, Z.; Zhang, Y.; Bravo, Y.; Weisinger, J.R.; Li, Y.C.; Rodriguez-Iturbe, B. Suppression of Renin–Angiotensin Gene Expression in the Kidney by Paricalcitol. Kidney International 2008, 74, 1394–1402. [Google Scholar] [CrossRef]
  72. Dusso, A.; Arcidiacono, M.V.; Yang, J.; Tokumoto, M. Vitamin D Inhibition of TACE and Prevention of Renal Osteodystrophy and Cardiovascular Mortality. The Journal of Steroid Biochemistry and Molecular Biology 2010, 121, 193–198. [Google Scholar] [CrossRef]
  73. Lind, L.; Hänni, A.; Lithell, H.; Hvarfner, A.; Sörensen, O.H.; Ljunghall, S. Vitamin D Is Related to Blood Pressure and Other Cardiovascular Risk Factors in Middle-Aged Men. Am J Hypertens 1995, 8, 894–901. [Google Scholar] [CrossRef]
  74. Resnick, L.M. Calcium-Regulating Hormones in Essential Hypertension: Relation to Plasma Renin Activity and Sodium Metabolism. Ann Intern Med 1986, 105, 649. [Google Scholar] [CrossRef]
  75. Kristal-Boneh, E.; Froom, P.; Harari, G.; Ribak, J. Association of Calcitriol and Blood Pressure in Normotensive Men. Hypertension 1997, 30, 1289–1294. [Google Scholar] [CrossRef]
  76. Kimura, Y.; Kawamura, M.; Owada, M.; Oshima, T.; Murooka, M.; Fujiwara, T.; Hiramori, K. Effectiveness of 1,25-Dihydroxyvitamin D Supplementation on Blood Pressure Reduction in a Pseudohypoparathyroidism Patient with High Renin Activity. Intern. Med. 1999, 38, 31–35. [Google Scholar] [CrossRef]
  77. Park, C.W.; Oh, Y.S.; Shin, Y.S.; Kim, C.-M.; Kim, Y.-S.; Kim, S.Y.; Choi, E.J.; Chang, Y.S.; Bang, B.K. Intravenous Calcitriol Regresses Myocardial Hypertrophy in Hemodialysis Patients with Secondary Hyperparathyroidism. American Journal of Kidney Diseases 1999, 33, 73–81. [Google Scholar] [CrossRef]
  78. Krause, R.; Bühring, M.; Hopfenmüller, W.; Holick, M.F.; Sharma, A.M. Ultraviolet B and Blood Pressure. The Lancet 1998, 352, 709–710. [Google Scholar] [CrossRef]
  79. Weber, K.T.; Rosenberg, E.W.; Sayre, R.M. Suberythemal Ultraviolet Exposure and Reduction in Blood Pressure. The American Journal of Medicine 2004, 117, 281–282. [Google Scholar] [CrossRef]
  80. Iseki, K. Proteinuria as a Predictor of Rapid eGFR Decline. Nat Rev Nephrol 2013, 9, 570–571. [Google Scholar] [CrossRef]
  81. Sarnak, M.J.; Astor, B.C. Implications of Proteinuria: CKD Progression and Cardiovascular Outcomes. Advances in Chronic Kidney Disease 2011, 18, 258–266. [Google Scholar] [CrossRef]
  82. Summary of Recommendation Statements. Kidney International Supplements 2013, 3, 5–14. [CrossRef]
  83. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S.; et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001, 345, 861–869. [Google Scholar] [CrossRef]
  84. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Engl J Med 2001, 345, 851–860. [Google Scholar] [CrossRef]
  85. Makani, H.; Bangalore, S.; Desouza, K.A.; Shah, A.; Messerli, F.H. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin System: Meta-Analysis of Randomised Trials. BMJ 2013, 346, f360–f360. [Google Scholar] [CrossRef]
  86. Fernandez Juarez, G.; Luño, J.; Barrio, V.; De Vinuesa, S.G.; Praga, M.; Goicoechea, M.; Cachofeiro, V.; Nieto, J.; Fernández Vega, F.; Tato, A.; et al. Effect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial. American Journal of Kidney Diseases 2013, 61, 211–218. [Google Scholar] [CrossRef]
  87. Parving, H.-H.; Brenner, B.M.; McMurray, J.J.V.; De Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med 2012, 367, 2204–2213. [Google Scholar] [CrossRef]
  88. Vitamina D y proteinuria: revisión crítica de las bases moleculares y de la experiencia clínica. Nefrología, 2013. [CrossRef]
  89. Matsui, I.; Hamano, T.; Tomida, K.; Inoue, K.; Takabatake, Y.; Nagasawa, Y.; Kawada, N.; Ito, T.; Kawachi, H.; Rakugi, H.; et al. Active Vitamin D and Its Analogue, 22-Oxacalcitriol, Ameliorate Puromycin Aminonucleoside-Induced Nephrosis in Rats. Nephrol Dial Transplant 2009, 24, 2354–2361. [Google Scholar] [CrossRef]
  90. Yamauchi, K.; Takano, Y.; Kasai, A.; Hayakawa, K.; Hiramatsu, N.; Enomoto, N.; Yao, J.; Kitamura, M. Screening and Identification of Substances That Regulate Nephrin Gene Expression Using Engineered Reporter Podocytes. Kidney Int 2006, 70, 892–900. [Google Scholar] [CrossRef]
  91. Liu, G.; Kaw, B.; Kurfis, J.; Rahmanuddin, S.; Kanwar, Y.S.; Chugh, S.S. Neph1 and Nephrin Interaction in the Slit Diaphragm Is an Important Determinant of Glomerular Permeability. J Clin Invest 2003, 112, 209–221. [Google Scholar] [CrossRef]
  92. Patrakka, J.; Tryggvason, K. Nephrin--a Unique Structural and Signaling Protein of the Kidney Filter. Trends Mol Med 2007, 13, 396–403. [Google Scholar] [CrossRef]
  93. Garofalo, C.; Secondulfo, C.; Apicella, L.; Bilancio, G.; De Nicola, L.; Minutolo, R.; Borrelli, S.; Provenzano, M.; Luciani, R.; Bellizzi, V. Antiproteinuric Effect of Paricalcitol in Kidney Transplant Recipients with Severe Proteinuria: A Prospective Cohort Study. J Nephrol 2022, 35, 1943–1945. [Google Scholar] [CrossRef] [PubMed]
  94. Alborzi, P.; Patel, N.A.; Peterson, C.; Bills, J.E.; Bekele, D.M.; Bunaye, Z.; Light, R.P.; Agarwal, R. Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial. Hypertension 2008, 52, 249–255. [Google Scholar] [CrossRef] [PubMed]
  95. Fishbane, S.; Chittineni, H.; Packman, M.; Dutka, P.; Ali, N.; Durie, N. Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial. American Journal of Kidney Diseases 2009, 54, 647–652. [Google Scholar] [CrossRef]
  96. De Zeeuw, D.; Agarwal, R.; Amdahl, M.; Audhya, P.; Coyne, D.; Garimella, T.; Parving, H.-H.; Pritchett, Y.; Remuzzi, G.; Ritz, E.; et al. Selective Vitamin D Receptor Activation with Paricalcitol for Reduction of Albuminuria in Patients with Type 2 Diabetes (VITAL Study): A Randomised Controlled Trial. The Lancet 2010, 376, 1543–1551. [Google Scholar] [CrossRef] [PubMed]
  97. Agarwal, R. Vitamin D, Proteinuria, Diabetic Nephropathy, and Progression of CKD. Clinical Journal of the American Society of Nephrology 2009, 4, 1523–1528. [Google Scholar] [CrossRef] [PubMed]
  98. Tan, X.; Wen, X.; Liu, Y. Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor–Mediated Sequestration of NF-κB Signaling. Journal of the American Society of Nephrology 2008, 19, 1741–1752. [Google Scholar] [CrossRef] [PubMed]
  99. Kheirouri, S.; Alizadeh, M. Vitamin D and Advanced Glycation End Products and Their Receptors. Pharmacological Research 2020, 158, 104879. [Google Scholar] [CrossRef]
  100. Fukami, K.; Taguchi, K.; Yamagishi, S.; Okuda, S. Receptor for Advanced Glycation Endproducts and Progressive Kidney Disease. Current Opinion in Nephrology and Hypertension 2015, 24, 54. [Google Scholar] [CrossRef] [PubMed]
  101. Visco, V.; Izzo, C.; Bonadies, D.; Di Feo, F.; Caliendo, G.; Loria, F.; Mancusi, C.; Chivasso, P.; Di Pietro, P.; Virtuoso, N.; et al. Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work. J Cardiovasc Dev Dis 2023, 10, 327. [Google Scholar] [CrossRef]
  102. Mathieu, C.; Adorini, L. The Coming of Age of 1,25-Dihydroxyvitamin D3 Analogs as Immunomodulatory Agents. Trends in Molecular Medicine 2002, 8, 174–179. [Google Scholar] [CrossRef]
  103. Penna, G.; Adorini, L. 1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. The Journal of Immunology 2000, 164, 2405–2411. [Google Scholar] [CrossRef] [PubMed]
  104. Sparaco, M.; Bonavita, S. Vitamin D Supplementation: Effect on Cytokine Profile in Multiple Sclerosis. JCM 2024, 13, 835. [Google Scholar] [CrossRef] [PubMed]
  105. Yeh, W.Z.; Lea, R.; Stankovich, J.; Sampangi, S.; Laverick, L.; Van Der Walt, A.; Jokubaitis, V.; Gresle, M.; Butzkueven, H. Transcriptomics Identifies Blunted Immunomodulatory Effects of Vitamin D in People with Multiple Sclerosis. Sci Rep 2024, 14, 1436. [Google Scholar] [CrossRef] [PubMed]
  106. Wei, Y.; Wang, T.; Nie, X.; Shi, Z.; Liu, Z.; Zeng, Y.; Pan, R.; Zhang, R.; Deng, Y.; Li, D. 1,25-Dihydroxyvitamin D3 Provides Benefits in Vitiligo Based on Modulation of CD8+ T Cell Glycolysis and Function. Nutrients 2023, 15, 4697. [Google Scholar] [CrossRef] [PubMed]
  107. Liu, W.-C.; Zheng, C.-M.; Lu, C.-L.; Lin, Y.-F.; Shyu, J.-F.; Wu, C.-C.; Lu, K.-C. Vitamin D and Immune Function in Chronic Kidney Disease. Clinica Chimica Acta 2015, 450, 135–144. [Google Scholar] [CrossRef] [PubMed]
  108. Széles, L.; Keresztes, G.; Töröcsik, D.; Balajthy, Z.; Krenács, L.; Póliska, S.; Steinmeyer, A.; Zuegel, U.; Pruenster, M.; Rot, A.; et al. 1,25-Dihydroxyvitamin D3 Is an Autonomous Regulator of the Transcriptional Changes Leading to a Tolerogenic Dendritic Cell Phenotype. J Immunol 2009, 182, 2074–2083. [Google Scholar] [CrossRef] [PubMed]
  109. Sterling, K.A.; Eftekhari, P.; Girndt, M.; Kimmel, P.L.; Raj, D.S. The Immunoregulatory Function of Vitamin D: Implications in Chronic Kidney Disease. Nat Rev Nephrol 2012, 8, 403–412. [Google Scholar] [CrossRef] [PubMed]
  110. Korf, H.; Wenes, M.; Stijlemans, B.; Takiishi, T.; Robert, S.; Miani, M.; Eizirik, D.L.; Gysemans, C.; Mathieu, C. 1,25-Dihydroxyvitamin D3 Curtails the Inflammatory and T Cell Stimulatory Capacity of Macrophages through an IL-10-Dependent Mechanism. Immunobiology 2012, 217, 1292–1300. [Google Scholar] [CrossRef] [PubMed]
  111. Morán-Auth, Y.; Penna-Martinez, M.; Shoghi, F.; Ramos-Lopez, E.; Badenhoop, K. Vitamin D Status and Gene Transcription in Immune Cells. J Steroid Biochem Mol Biol 2013, 136, 83–85. [Google Scholar] [CrossRef]
  112. Kim, H.; Kang, S.-W.; Yoo, T.-H.; Kim, M.S.; Kim, S.I.; Kim, Y.S.; Choi, K.H. The Impact of Pretransplant 25-Hydroxy Vitamin D Deficiency on Subsequent Graft Function: An Observational Study. BMC Nephrol 2012, 13, 22. [Google Scholar] [CrossRef]
  113. Bienaimé, F.; Girard, D.; Anglicheau, D.; Canaud, G.; Souberbielle, J.C.; Kreis, H.; Noël, L.H.; Friedlander, G.; Elie, C.; Legendre, C.; et al. Vitamin D Status and Outcomes after Renal Transplantation. J Am Soc Nephrol 2013, 24, 831–841. [Google Scholar] [CrossRef] [PubMed]
  114. Lee, J.R.; Dadhania, D.; August, P.; Lee, J.B.; Suthanthiran, M.; Muthukumar, T. Circulating Levels of 25-Hydroxyvitamin D and Acute Cellular Rejection in Kidney Allograft Recipients. Transplantation 2014, 98, 292–299. [Google Scholar] [CrossRef] [PubMed]
  115. Keyzer, C.A.; Riphagen, I.J.; Joosten, M.M.; Navis, G.; Muller Kobold, A.C.; Kema, I.P.; Bakker, S.J.L.; de Borst, M.H. ; NIGRAM consortium Associations of 25(OH) and 1,25(OH)2 Vitamin D with Long-Term Outcomes in Stable Renal Transplant Recipients. J Clin Endocrinol Metab 2015, 100, 81–89. [Google Scholar] [CrossRef]
  116. Wood, D. Established and Emerging Cardiovascular Risk Factors. American Heart Journal 2001, 141, S49–S57. [Google Scholar] [CrossRef] [PubMed]
  117. Izzo, C.; Visco, V.; Gambardella, J.; Ferruzzi, G.J.; Rispoli, A.; Rusciano, M.R.; Toni, A.L.; Virtuoso, N.; Carrizzo, A.; Di Pietro, P.; et al. Cardiovascular Implications of microRNAs in Coronavirus Disease 2019. J Pharmacol Exp Ther 2023, 384, 102–108. [Google Scholar] [CrossRef] [PubMed]
  118. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018, 39, 3021–3104. [Google Scholar] [CrossRef] [PubMed]
  119. Legarth, C.; Grimm, D.; Krüger, M.; Infanger, M.; Wehland, M. Potential Beneficial Effects of Vitamin D in Coronary Artery Disease. Nutrients 2019, 12, 99. [Google Scholar] [CrossRef] [PubMed]
  120. Rai, V.; Agrawal, D.K. Role of Vitamin D in Cardiovascular Diseases. Endocrinology and Metabolism Clinics of North America 2017, 46, 1039–1059. [Google Scholar] [CrossRef] [PubMed]
  121. Wimalawansa, S.J. Vitamin D and Cardiovascular Diseases: Causality. The Journal of Steroid Biochemistry and Molecular Biology 2018, 175, 29–43. [Google Scholar] [CrossRef] [PubMed]
  122. McMullan, C.J.; Borgi, L.; Curhan, G.C.; Fisher, N.; Forman, J.P. The Effect of Vitamin D on Renin-Angiotensin System Activation and Blood Pressure: A Randomized Control Trial. J Hypertens 2017, 35, 822–829. [Google Scholar] [CrossRef]
  123. Carrizzo, A.; Moltedo, O.; Damato, A.; Martinello, K.; Di Pietro, P.; Oliveti, M.; Acernese, F.; Giugliano, G.; Izzo, R.; Sommella, E.; et al. New Nutraceutical Combination Reduces Blood Pressure and Improves Exercise Capacity in Hypertensive Patients Via a Nitric Oxide-Dependent Mechanism. J Am Heart Assoc 2020, 9, e014923. [Google Scholar] [CrossRef] [PubMed]
  124. Lavie, C.J.; DiNicolantonio, J.J.; Milani, R.V.; O’Keefe, J.H. Vitamin D and Cardiovascular Health. Circulation 2013, 128, 2404–2406. [Google Scholar] [CrossRef] [PubMed]
  125. Jorde, R.; Sundsfjord, J.; Haug, E.; Bønaa, K.H. Relation Between Low Calcium Intake, Parathyroid Hormone, and Blood Pressure. Hypertension 2000, 35, 1154–1159. [Google Scholar] [CrossRef] [PubMed]
  126. Barbarawi, M.; Kheiri, B.; Zayed, Y.; Barbarawi, O.; Dhillon, H.; Swaid, B.; Yelangi, A.; Sundus, S.; Bachuwa, G.; Alkotob, M.L.; et al. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-Analysis. JAMA Cardiol 2019, 4, 765. [Google Scholar] [CrossRef] [PubMed]
  127. De Boer, I.H.; Kestenbaum, B.; Shoben, A.B.; Michos, E.D.; Sarnak, M.J.; Siscovick, D.S. 25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification. Journal of the American Society of Nephrology 2009, 20, 1805–1812. [Google Scholar] [CrossRef] [PubMed]
  128. Zehnder, D.; Bland, R.; Chana, R.S.; Wheeler, D.C.; Howie, A.J.; Williams, M.C.; Stewart, P.M.; Hewison, M. Synthesis of 1,25-Dihydroxyvitamin D3 by Human Endothelial Cells Is Regulated by Inflammatory Cytokines: A Novel Autocrine Determinant of Vascular Cell Adhesion. Journal of the American Society of Nephrology 2002, 13, 621–629. [Google Scholar] [CrossRef] [PubMed]
  129. De Falco, E.; Carnevale, R.; Pagano, F.; Chimenti, I.; Fianchini, L.; Bordin, A.; Siciliano, C.; Monticolo, R.; Equitani, F.; Carrizzo, A.; et al. Role of NOX2 in Mediating Doxorubicin-Induced Senescence in Human Endothelial Progenitor Cells. Mech Ageing Dev 2016, 159, 37–43. [Google Scholar] [CrossRef] [PubMed]
  130. Dao, H.; Essalihi, R.; Bouvet, C.; Moreau, P. Evolution and Modulation of Age-Related Medial Elastocalcinosis: Impact on Large Artery Stiffness and Isolated Systolic Hypertension. Cardiovascular Research 2005, 66, 307–317. [Google Scholar] [CrossRef]
  131. Jono, S.; Nishizawa, Y.; Shioi, A.; Morii, H. 1,25-Dihydroxyvitamin D 3 Increases In Vitro Vascular Calcification by Modulating Secretion of Endogenous Parathyroid Hormone–Related Peptide. Circulation 1998, 98, 1302–1306. [Google Scholar] [CrossRef]
  132. Yamamoto, T.; Kozawa, O.; Tanabe, K.; Akamatsu, S.; Matsuno, H.; Dohi, S.; Hirose, H.; Uematsu, T. 1,25-Dihydroxyvitamin D3 Stimulates Vascular Endothelial Growth Factor Release in Aortic Smooth Muscle Cells: Role of P38 Mitogen-Activated Protein Kinase. Archives of Biochemistry and Biophysics 2002, 398, 1–6. [Google Scholar] [CrossRef]
  133. Di Pietro, P.; Abate, A.C.; Prete, V.; Damato, A.; Venturini, E.; Rusciano, M.R.; Izzo, C.; Visco, V.; Ciccarelli, M.; Vecchione, C.; et al. C2CD4B Evokes Oxidative Stress and Vascular Dysfunction via a PI3K/Akt/PKCα-Signaling Pathway. Antioxidants (Basel) 2024, 13, 101. [Google Scholar] [CrossRef] [PubMed]
  134. Jensen, N.S.; Wehland, M.; Wise, P.M.; Grimm, D. Latest Knowledge on the Role of Vitamin D in Hypertension. Int J Mol Sci 2023, 24, 4679. [Google Scholar] [CrossRef] [PubMed]
  135. Glass, C.K.; Witztum, J.L. Atherosclerosis. Cell 2001, 104, 503–516. [Google Scholar] [CrossRef] [PubMed]
  136. Di Pietro, P.; Izzo, C.; Abate, A.C.; Iesu, P.; Rusciano, M.R.; Venturini, E.; Visco, V.; Sommella, E.; Ciccarelli, M.; Carrizzo, A.; et al. The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers. Biomolecules 2023, 13, 168. [Google Scholar] [CrossRef] [PubMed]
  137. Di Pietro, P.; Lizio, R.; Izzo, C.; Visco, V.; Damato, A.; Venturini, E.; De Lucia, M.; Galasso, G.; Migliarino, S.; Rasile, B.; et al. A Novel Combination of High-Load Omega-3 Lysine Complex (AvailOm®) and Anthocyanins Exerts Beneficial Cardiovascular Effects. Antioxidants (Basel) 2022, 11, 896. [Google Scholar] [CrossRef] [PubMed]
  138. Falk, E. Pathogenesis of Atherosclerosis. Journal of the American College of Cardiology 2006, 47, C7–C12. [Google Scholar] [CrossRef] [PubMed]
  139. Pál, É.; Ungvári, Z.; Benyó, Z.; Várbíró, S. Role of Vitamin D Deficiency in the Pathogenesis of Cardiovascular and Cerebrovascular Diseases. Nutrients 2023, 15, 334. [Google Scholar] [CrossRef] [PubMed]
  140. Andrukhova, O.; Slavic, S.; Zeitz, U.; Riesen, S.C.; Heppelmann, M.S.; Ambrisko, T.D.; Markovic, M.; Kuebler, W.M.; Erben, R.G. Vitamin D Is a Regulator of Endothelial Nitric Oxide Synthase and Arterial Stiffness in Mice. Molecular Endocrinology 2014, 28, 53–64. [Google Scholar] [CrossRef]
  141. Carthy, E.P.; Yamashita, W.; Hsu, A.; Ooi, B.S. 1,25-Dihydroxyvitamin D3 and Rat Vascular Smooth Muscle Cell Growth. Hypertension 1989, 13, 954–959. [Google Scholar] [CrossRef]
  142. Raymond, M.-A.; Désormeaux, A.; Labelle, A.; Soulez, M.; Soulez, G.; Langelier, Y.; Pshezhetsky, A.V.; Hébert, M.-J. Endothelial Stress Induces the Release of Vitamin D-Binding Protein, a Novel Growth Factor. Biochem Biophys Res Commun 2005, 338, 1374–1382. [Google Scholar] [CrossRef]
  143. Bobryshev, Y.V. Vitamin D 3 Suppresses Immune Reactions in Atherosclerosis, Affecting Regulatory T Cells and Dendritic Cell Function. ATVB 2010, 30, 2317–2319. [Google Scholar] [CrossRef] [PubMed]
  144. Watson, K.E.; Abrolat, M.L.; Malone, L.L.; Hoeg, J.M.; Doherty, T.; Detrano, R.; Demer, L.L. Active Serum Vitamin D Levels Are Inversely Correlated With Coronary Calcification. Circulation 1997, 96, 1755–1760. [Google Scholar] [CrossRef] [PubMed]
  145. Roger, V.L. Epidemiology of Heart Failure. Circulation Research 2021, 128, 1421–1434. [Google Scholar] [CrossRef] [PubMed]
  146. Schwinger, R.H.G. Pathophysiology of Heart Failure. Cardiovasc Diagn Ther 2021, 11, 263–276. [Google Scholar] [CrossRef]
  147. Hazique, M.; Khan, K.I.; Ramesh, P.; Kanagalingam, S.; Zargham Ul Haq, F.; Victory Srinivasan, N.; Khan, A.I.; Mashat, G.D.; Khan, S. A Study of Vitamin D and Its Correlation With Severity and Complication of Congestive Heart Failure: A Systematic Review. Cureus 2022. [Google Scholar] [CrossRef]
  148. Campanile, A.; Visco, V.; De Carlo, S.; Ferruzzi, G.J.; Mancusi, C.; Izzo, C.; Mongiello, F.; Di Pietro, P.; Virtuoso, N.; Ravera, A.; et al. Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life (Basel) 2023, 13, 1174. [Google Scholar] [CrossRef]
  149. Qu, H.; Lin, K.; Wang, H.; Wei, H.; Ji, B.; Yang, Z.; Peng, C.; Xiao, X.; Deng, H. 1,25(OH)2D3 Improves Cardiac Dysfunction, Hypertrophy, and Fibrosis through PARP1/SIRT1/mTOR-Related Mechanisms in Type 1 Diabetes. Molecular Nutrition & Food Research 2017, 61, 1600338. [Google Scholar] [CrossRef]
  150. Chen, S.; Law, C.S.; Grigsby, C.L.; Olsen, K.; Hong, T.-T.; Zhang, Y.; Yeghiazarians, Y.; Gardner, D.G. Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation 2011, 124, 1838–1847. [Google Scholar] [CrossRef]
  151. Schroten, N.F.; Ruifrok, W.P.T.; Kleijn, L.; Dokter, M.M.; Silljé, H.H.; Lambers Heerspink, H.J.; Bakker, S.J.L.; Kema, I.P.; Van Gilst, W.H.; Van Veldhuisen, D.J.; et al. Short-Term Vitamin D3 Supplementation Lowers Plasma Renin Activity in Patients with Stable Chronic Heart Failure: An Open-Label, Blinded End Point, Randomized Prospective Trial (VitD-CHF Trial). American Heart Journal 2013, 166, 357–364. [Google Scholar] [CrossRef]
  152. Mahmood, S.S.; Levy, D.; Vasan, R.S.; Wang, T.J. The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. The Lancet 2014, 383, 999–1008. [Google Scholar] [CrossRef]
  153. Brøndum-Jacobsen, P.; Benn, M.; Jensen, G.B.; Nordestgaard, B.G. 25-Hydroxyvitamin d Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death: Population-Based Study and Meta-Analyses of 18 and 17 Studies. Arterioscler Thromb Vasc Biol 2012, 32, 2794–2802. [Google Scholar] [CrossRef]
  154. Ameri, P.; Canepa, M.; Milaneschi, Y.; Spallarossa, P.; Leoncini, G.; Giallauria, F.; Strait, J.B.; Lakatta, E.G.; Brunelli, C.; Murialdo, G.; et al. Relationship between Vitamin D Status and Left Ventricular Geometry in a Healthy Population: Results from the Baltimore Longitudinal Study of Aging. Journal of Internal Medicine 2013, 273, 253–262. [Google Scholar] [CrossRef] [PubMed]
  155. Şeker, T.; Gür, M.; Uçar, H.; Türkoğlu, C.; Oytun Baykan, A.; Özaltun, B.; Harbalıoğlu, H.; Yüksel Kalkan, G.; Kaypaklı, O.; Kuloğlu, O.; et al. Lower Serum 25-Hydroxyvitamin D Level Is Associated with Impaired Myocardial Performance and Left Ventricle Hypertrophy in Newly Diagnosed Hypertensive Patients. The Anatolian Journal of Cardiology 2015, 15, 744–750. [Google Scholar] [CrossRef]
  156. Moretti, H.D.; Colucci, V.J.; Berry, B.D. Vitamin D3 Repletion versus Placebo as Adjunctive Treatment of Heart Failure Patient Quality of Life and Hormonal Indices: A Randomized, Double-Blind, Placebo-Controlled Trial. BMC Cardiovasc Disord 2017, 17, 274. [Google Scholar] [CrossRef] [PubMed]
  157. Hahn, J.; Cook, N.R.; Alexander, E.K.; Friedman, S.; Walter, J.; Bubes, V.; Kotler, G.; Lee, I.-M.; Manson, J.E.; Costenbader, K.H. Vitamin D and Marine Omega 3 Fatty Acid Supplementation and Incident Autoimmune Disease: VITAL Randomized Controlled Trial. BMJ 2022, 376, e066452. [Google Scholar] [CrossRef] [PubMed]
  158. Scragg, R.; Stewart, A.W.; Waayer, D.; Lawes, C.M.M.; Toop, L.; Sluyter, J.; Murphy, J.; Khaw, K.-T.; Camargo, C.A. , Jr Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. JAMA Cardiology 2017, 2, 608–616. [Google Scholar] [CrossRef]
  159. Zittermann, A.; Ernst, J.B.; Prokop, S.; Fuchs, U.; Dreier, J.; Kuhn, J.; Knabbe, C.; Birschmann, I.; Schulz, U.; Berthold, H.K.; et al. Effect of Vitamin D on All-Cause Mortality in Heart Failure (EVITA): A 3-Year Randomized Clinical Trial with 4000 IU Vitamin D Daily. European Heart Journal 2017, 38, 2279–2286. [Google Scholar] [CrossRef]
  160. Avenell, A.; MacLennan, G.S.; Jenkinson, D.J.; McPherson, G.C.; McDonald, A.M.; Pant, P.R.; Grant, A.M.; Campbell, M.K.; Anderson, F.H.; Cooper, C.; et al. Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). The Journal of Clinical Endocrinology & Metabolism 2012, 97, 614–622. [Google Scholar] [CrossRef]
  161. Witte, K.K.; Byrom, R.; Gierula, J.; Paton, M.F.; Jamil, H.A.; Lowry, J.E.; Gillott, R.G.; Barnes, S.A.; Chumun, H.; Kearney, L.C.; et al. Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study. J Am Coll Cardiol 2016, 67, 2593–2603. [Google Scholar] [CrossRef]
  162. Gómez-Outes, A.; Lagunar-Ruíz, J.; Terleira-Fernández, A.-I.; Calvo-Rojas, G.; Suárez-Gea, M.L.; Vargas-Castrillón, E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology 2016, 68, 2508–2521. [Google Scholar] [CrossRef]
  163. Andrade, J.; Khairy, P.; Dobrev, D.; Nattel, S. The Clinical Profile and Pathophysiology of Atrial Fibrillation: Relationships Among Clinical Features, Epidemiology, and Mechanisms. Circ Res 2014, 114, 1453–1468. [Google Scholar] [CrossRef]
  164. Visco, V.; Izzo, C.; Mancusi, C.; Rispoli, A.; Tedeschi, M.; Virtuoso, N.; Giano, A.; Gioia, R.; Melfi, A.; Serio, B.; et al. Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve. J Cardiovasc Dev Dis 2023, 10, 74. [Google Scholar] [CrossRef] [PubMed]
  165. Qayyum, F.; Landex, N.L.; Agner, B.R.; Rasmussen, M.; Jøns, C.; Dixen, U. Vitamin D Deficiency Is Unrelated to Type of Atrial Fibrillation and Its Complications. Dan Med J 2012, 59, A4505. [Google Scholar]
  166. Smith, M.B.; May, H.T.; Blair, T.L.; Anderson, J.L.; Muhlestein, J.B.; Horne, B.D.; Lappe, D.L.; Day, J.D.; Crandall, B.G.; Weiss, P.; et al. Abstract 14699: Vitamin D Excess Is Significantly Associated with Risk of Atrial Fibrillation. Circulation 2011, 124, A14699–A14699. [Google Scholar] [CrossRef]
  167. Thompson, J.; Nitiahpapand, R.; Bhatti, P.; Kourliouros, A. Vitamin D Deficiency and Atrial Fibrillation. International Journal of Cardiology 2015, 184, 159–162. [Google Scholar] [CrossRef]
  168. Funk Casmir, null The Journal of State Medicine. Volume XX: 341-368, 1912. The Etiology of the Deficiency Diseases, Beri-Beri, Polyneuritis in Birds, Epidemic Dropsy, Scurvy, Experimental Scurvy in Animals, Infantile Scurvy, Ship Beri-Beri, Pellagra. Nutr Rev 1975, 33, 176–177. [Google Scholar] [CrossRef]
  169. Santulli, G.; Pascale, V.; Finelli, R.; Visco, V.; Giannotti, R.; Massari, A.; Morisco, C.; Ciccarelli, M.; Illario, M.; Iaccarino, G.; et al. We Are What We Eat: Impact of Food from Short Supply Chain on Metabolic Syndrome. J Clin Med 2019, 8, 2061. [Google Scholar] [CrossRef] [PubMed]
  170. Marcén, R.; Jimenez, S.; Fernández-Rodriguez, A.; Galeano, C.; Villafruela, J.J.; Gomis, A.; Teruel, J.L.; Quereda, C. Are Low Levels of 25-Hydroxyvitamin D a Risk Factor for Cardiovascular Diseases or Malignancies in Renal Transplantation? Nephrol Dial Transplant 2012, 27 Suppl 4, iv47–52. [Google Scholar] [CrossRef]
  171. Mann, M.C.; Exner, D.V.; Hemmelgarn, B.R.; Hanley, D.A.; Turin, T.C.; MacRae, J.M.; Wheeler, D.C.; Sola, D.Y.; Ramesh, S.; Ahmed, S.B. The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial. Nutrients 2016, 8, 608. [Google Scholar] [CrossRef] [PubMed]
  172. Muscogiuri, G.; Altieri, B.; Annweiler, C.; Balercia, G.; Pal, H.B.; Boucher, B.J.; Cannell, J.J.; Foresta, C.; Grübler, M.R.; Kotsa, K.; et al. Vitamin D and Chronic Diseases: The Current State of the Art. Arch Toxicol 2017, 91, 97–107. [Google Scholar] [CrossRef]
  173. Lappe, J.; Watson, P.; Travers-Gustafson, D.; Recker, R.; Garland, C.; Gorham, E.; Baggerly, K.; McDonnell, S.L. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA 2017, 317, 1234–1243. [Google Scholar] [CrossRef] [PubMed]
  174. Atkinson, M.A.; Juraschek, S.P.; Bertenthal, M.S.; Detrick, B.; Furth, S.L.; Miller, E.R. Pilot Study of the Effect of Cholecalciferol Supplementation on Hepcidin in Children with Chronic Kidney Disease: Results of the D-Fense Trial. Pediatr Nephrol 2017, 32, 859–868. [Google Scholar] [CrossRef] [PubMed]
  175. Theodoratou, E.; Tzoulaki, I.; Zgaga, L.; Ioannidis, J.P.A. Vitamin D and Multiple Health Outcomes: Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies and Randomised Trials. BMJ 2014, 348, g2035. [Google Scholar] [CrossRef] [PubMed]
  176. Marcinowska-Suchowierska, E.; Kupisz-Urbańska, M.; Łukaszkiewicz, J.; Płudowski, P.; Jones, G. Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne) 2018, 9, 550. [Google Scholar] [CrossRef] [PubMed]
  177. Chiricone, D.; De Santo, N.G.; Cirillo, M. Unusual Cases of Chronic Intoxication by Vitamin D. J Nephrol 2003, 16, 917–921. [Google Scholar]
  178. Cirillo, M.; Bilancio, G.; Cirillo, C. Reversible Vascular Calcifications Associated with Hypervitaminosis D. J Nephrol 2016, 29, 129–131. [Google Scholar] [CrossRef]
Preprints 103007 g001
Figure 1. The complex formed by 1,25(OH)2D3–VDR2 dimerizes with the retinoid X receptor (RXR) and relocates to the nucleus. There, it binds to vitamin D response elements (VDRE) present in the promoter region of target genes. 25(OH)D sourced from the bloodstream may undergo local conversion into 1,25(OH) D within cells that express 1α-hydroxylase. Adapted from Latic[29].
Figure 1. The complex formed by 1,25(OH)2D3–VDR2 dimerizes with the retinoid X receptor (RXR) and relocates to the nucleus. There, it binds to vitamin D response elements (VDRE) present in the promoter region of target genes. 25(OH)D sourced from the bloodstream may undergo local conversion into 1,25(OH) D within cells that express 1α-hydroxylase. Adapted from Latic[29].
Preprints 103007 g001
Preprints 103007 g002
Figure 2. Mechanisms underlying vitamin D deficiency in CKD. VDBP: vitamin D binding protein. Adapted from Brandenburg[56].
Figure 2. Mechanisms underlying vitamin D deficiency in CKD. VDBP: vitamin D binding protein. Adapted from Brandenburg[56].
Preprints 103007 g002
Preprints 103007 g003
Figure 3. Schematic representation of Vitamin D inhibition of RAAS. ACE, angiotensin converting enzyme; AT1, angiotensin receptor type 1; PRR, prorenin receptor; TACE, tumor necrosis factor α converting enzyme.
Figure 3. Schematic representation of Vitamin D inhibition of RAAS. ACE, angiotensin converting enzyme; AT1, angiotensin receptor type 1; PRR, prorenin receptor; TACE, tumor necrosis factor α converting enzyme.
Preprints 103007 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated